ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Many patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) experience a delay in treatment or fail to initiate treatment with guideline-recommended angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) after CKD diagnosis. This study aimed to describe treatment patterns and treatment initiation after initial CKD diagnosis among patients with T2D.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Am J Manag Care

Title: The American journal of managed care

Publisher: Managed Care and Healthcare Communications, LLC

ISSN (Electronic): 1936-2692

ISSN (Print): 1088-0224

Publication date (Electronic): December 2021

Volume: 27

Issue: 20 Suppl

Affiliations

[1 ] University of Tennessee Health Science Center, Memphis, TN. Email: ckovesdy@uthsc.edu.

Article

Publisher Item ID: 88806

DOI: 10.37765/ajmc.2021.88806

PubMed ID: 34878753

SO-VID: 680c752c-066e-4304-b749-0250f9e81b24

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 4

See all cited by